CS930586A2 - Zpusob vyroby monohydratu n,n dimethyl 1 ( 1 ( 4 chlorfenyl ) cyklobutyl ) 3 methylbutylamin hydrochloridu - Google Patents

Zpusob vyroby monohydratu n,n dimethyl 1 ( 1 ( 4 chlorfenyl ) cyklobutyl ) 3 methylbutylamin hydrochloridu

Info

Publication number
CS930586A2
CS930586A2 CS869305A CS930586A CS930586A2 CS 930586 A2 CS930586 A2 CS 930586A2 CS 869305 A CS869305 A CS 869305A CS 930586 A CS930586 A CS 930586A CS 930586 A2 CS930586 A2 CS 930586A2
Authority
CS
Czechoslovakia
Prior art keywords
dimethyl
monohydratu
methylbutylamin
hydrochloridu
cyklobutyl
Prior art date
Application number
CS869305A
Other languages
English (en)
Other versions
CS259545B2 (en
Inventor
James E Jeffery
Derek Whybrow
Original Assignee
Boots Co Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10589895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CS930586(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boots Co Plc filed Critical Boots Co Plc
Publication of CS930586A2 publication Critical patent/CS930586A2/cs
Publication of CS259545B2 publication Critical patent/CS259545B2/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
CS869305A 1985-12-17 1986-12-15 Method of n,n-dimethyl-1-(1-/chlorphenyl/ cyclobutyl)-3-methylbutyl-amin-hydrochloride's monohydrate production CS259545B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858531071A GB8531071D0 (en) 1985-12-17 1985-12-17 Therapeutic compound

Publications (2)

Publication Number Publication Date
CS930586A2 true CS930586A2 (en) 1988-02-15
CS259545B2 CS259545B2 (en) 1988-10-14

Family

ID=10589895

Family Applications (1)

Application Number Title Priority Date Filing Date
CS869305A CS259545B2 (en) 1985-12-17 1986-12-15 Method of n,n-dimethyl-1-(1-/chlorphenyl/ cyclobutyl)-3-methylbutyl-amin-hydrochloride's monohydrate production

Country Status (34)

Country Link
US (2) US4929629A (cs)
EP (1) EP0230742B1 (cs)
JP (1) JPS62155240A (cs)
KR (1) KR940008913B1 (cs)
CN (1) CN1016245B (cs)
AT (1) ATE56942T1 (cs)
AU (1) AU601167B2 (cs)
CA (1) CA1266278A (cs)
CS (1) CS259545B2 (cs)
DD (1) DD263050A5 (cs)
DE (1) DE3674570D1 (cs)
DK (1) DK170770B1 (cs)
EG (1) EG17770A (cs)
ES (1) ES2018163T4 (cs)
FI (1) FI90413C (cs)
GB (1) GB8531071D0 (cs)
GE (1) GEP19970812B (cs)
GR (1) GR3001069T3 (cs)
HU (1) HU201901B (cs)
IE (1) IE59429B1 (cs)
IL (1) IL80934A (cs)
IN (1) IN163129B (cs)
LU (1) LU90865I2 (cs)
MX (1) MX4684A (cs)
NL (1) NL300065I1 (cs)
NO (2) NO165540C (cs)
NZ (1) NZ218578A (cs)
PH (1) PH22481A (cs)
PL (1) PL149519B1 (cs)
PT (1) PT83958B (cs)
SU (1) SU1443796A3 (cs)
UA (1) UA7206A1 (cs)
YU (1) YU46033B (cs)
ZA (1) ZA869078B (cs)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
EP0647134A4 (en) * 1992-06-23 1997-07-30 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING DEPRESSION AND OTHER DISEASES USING OPTICALLY PURE SIBUTRAMINE.
JPH07508281A (ja) * 1992-06-23 1995-09-14 セプラコア　インコーポレーテッド 光学的に純粋な（＋）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE4443891A1 (de) 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
BR0007633A (pt) * 1999-01-20 2002-01-02 Knoll Pharmaceutical Co Processo para ajudar a parar de fumar
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
US6372798B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
WO2000056310A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
PL351958A1 (en) * 1999-03-19 2003-07-14 Knoll Gmbh Treatment of some tumours associated with gain in weight
US6441046B1 (en) 1999-03-19 2002-08-27 Abbott Gmbh & Co. Kg Control of metabolism
WO2000056308A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Prevention of cardiovascular disease
WO2000056315A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of pain
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US6376554B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Method of treating sexual dysfunction
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6365632B1 (en) 1999-03-19 2002-04-02 Knoll Pharmaceuticals Company Treatment of orthostatic hypotension
EP1169029B1 (en) * 1999-03-19 2005-05-04 Abbott GmbH & Co. KG Use of sibutramine or its derivative for the treatment of sleep disorders
WO2000056312A1 (en) 1999-03-19 2000-09-28 Knoll Gmbh Treatment of pulmonary hypertension
BR0009081A (pt) * 1999-03-19 2003-03-05 Knoll Gmbh Tratamento de osteoartrite
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
PE20011061A1 (es) 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
US6610887B2 (en) * 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
NZ534757A (en) * 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
PL375032A1 (en) * 2002-10-05 2005-11-14 Hanmi Pharm.Co, Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
GB0310361D0 (en) * 2003-05-06 2003-06-11 Cipla Ltd Pharmaceutical compound
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
ATE439347T1 (de) * 2004-11-23 2009-08-15 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
US7432398B2 (en) 2005-01-06 2008-10-07 Cj Corporation Inorganic acid salts of sibutramine
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
KR100781882B1 (ko) * 2005-07-12 2007-12-05 주식회사유한양행 시부트라민을 함유하는 약제학적 조성물
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
US20090203738A1 (en) * 2005-09-22 2009-08-13 Eisai R&D Management Co., Ltd. Pharmaceutical Composition for Treating Bulimia and Depression Arising from Bulimia
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
MEP6808A (xx) * 2006-02-23 2010-02-10 Lundbeck & Co As H Priperidinoilpirodolini agonisti receptora menalokortina tipa 4
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
MX2009002781A (es) * 2006-09-15 2009-03-30 Reviva Pharmaceuticals Inc Sintesis, metodos de uso y composiciones de cicloalquilmetilaminas .
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
EP2084127A1 (en) 2006-11-13 2009-08-05 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
KR20090083477A (ko) * 2006-11-20 2009-08-03 그렌마크 파머수티칼스 에스. 아. 스테아로일-ＣｏＡ 불포화효소 저해제인 아세틸렌 유도체
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
US20080221057A1 (en) * 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
AU2008236616A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
US8592403B2 (en) * 2008-08-06 2013-11-26 Pfizer Limited Diazepine and diazocane compounds as MC4 agonists
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US20120053172A1 (en) 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
AU2010310956B2 (en) 2009-11-02 2014-05-08 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US20120070465A1 (en) 2010-03-29 2012-03-22 Astellas Pharma Inc. Pharmaceutical composition for modified release
CA2802832A1 (en) 2010-07-06 2012-01-12 Astrazeneca Ab Therapeutic agents 976
EP3777864A1 (en) 2010-11-04 2021-02-17 Albireo AB Ibat inhibitors for the treatment of liver diseases
KR101890960B1 (ko) 2010-11-08 2018-09-28 알비레오 에이비 Ⅰｂａｔ 억제제 및 담즙산 바인더를 포함하는 약학적 조합물
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
CN110372522B (zh) * 2019-07-30 2020-10-02 南京工业大学 一种从含有戊二胺的固相中汽提回收戊二胺的方法
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (de) * 1960-02-12 1962-03-01 Hoechst Ag Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen
SE7600674L (sv) * 1975-02-05 1976-08-06 Rohm & Haas Fungicider
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB2115409B (en) * 1982-02-24 1985-08-07 Zyma Sa Novel crystal modifications of (+)-catechin
DK101683A (da) * 1982-03-12 1983-09-13 Duphar Int Res Phenylpiperazinderivater og fremgangsmaade til fremstilling heraf
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Also Published As

Publication number Publication date
ES2018163T4 (es) 2012-06-14
PH22481A (en) 1988-09-12
IL80934A (en) 1990-07-26
FI90413C (fi) 1994-02-10
AU601167B2 (en) 1990-09-06
DE3674570D1 (de) 1990-10-31
GB8531071D0 (en) 1986-01-29
NL300065I1 (nl) 2001-12-01
IE59429B1 (en) 1994-02-23
HUT45964A (en) 1988-09-28
KR870005961A (ko) 1987-07-08
PT83958A (en) 1987-01-01
DD263050A5 (de) 1988-12-21
CN86108547A (zh) 1987-08-19
NO2005022I1 (no) 2005-10-03
CS259545B2 (en) 1988-10-14
FI865030L (fi) 1987-06-18
UA7206A1 (uk) 1995-06-30
NO865093L (no) 1987-06-18
JPS62155240A (ja) 1987-07-10
GR3001069T3 (en) 1992-03-20
DK585786A (da) 1987-06-18
DK585786D0 (da) 1986-12-05
IE863102L (en) 1987-06-17
US4929629A (en) 1990-05-29
JPH0144176B2 (cs) 1989-09-26
NO165540B (no) 1990-11-19
NZ218578A (en) 1989-04-26
FI865030A0 (fi) 1986-12-10
YU205086A (en) 1987-12-31
DK170770B1 (da) 1996-01-15
CN1016245B (zh) 1992-04-15
EG17770A (en) 1991-03-30
FI90413B (fi) 1993-10-29
YU46033B (sh) 1992-12-21
PL149519B1 (en) 1990-02-28
ATE56942T1 (de) 1990-10-15
CA1266278A (en) 1990-02-27
PL263020A1 (en) 1988-05-12
NO165540C (no) 1991-02-27
EP0230742B1 (en) 1990-09-26
ES2018163B3 (es) 1991-04-01
GEP19970812B (en) 1997-02-10
LU90865I2 (fr) 2002-02-18
AU6644286A (en) 1987-06-18
PT83958B (pt) 1989-05-12
KR940008913B1 (ko) 1994-09-28
US5068440A (en) 1991-11-26
EP0230742A1 (en) 1987-08-05
HU201901B (en) 1991-01-28
SU1443796A3 (ru) 1988-12-07
IN163129B (cs) 1988-08-13
ZA869078B (en) 1987-07-29
NO865093D0 (no) 1986-12-16
MX4684A (es) 1993-12-01

Similar Documents

Publication Publication Date Title
CS930586A2 (en) Zpusob vyroby monohydratu n,n dimethyl 1 ( 1 ( 4 chlorfenyl ) cyklobutyl ) 3 methylbutylamin hydrochloridu
CA2003524A1 (en) Treatment of obesity
ZA907338B (en) Thienylcarboxylates of amino alcohols
SG2295G (en) Metropolol succinate and pharmaceutical composition containing it
PH25126A (en) 1,5-diaryl-3-substituted pyrazoles pharmaceutical compositions and use
ITRM930752A0 (it) Cartuccia a perdere di orecchini per la foratura del lobo auricolare erelativi fermi integrata con morsetto di presa auricolare.
ZA88186B (en) Brompheniramine,pseudoephedrine therapy
NZ212067A (en) Derivatives of glycerophosphocholine and glycerophosphoethanolamine; preparation and use
USD290312S (en) Combined toothbrush and dental floss holder
DE3063339D1 (en) Peptides with pharmacological activity and medicines containing them
GB2184122B (en) N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
USD277979S (en) Amino acid analyzer
USD281452S (en) Orthodontic archwire cutter
HRP930745B1 (en) New non-hygroscopic form of n,n-dimethyl-1-/1-(4-chlorophenyl) cyclobuthyl)-3-methylbutylamine hydrochloride
IT216623Z2 (it) Fermaglio di estremita' del cerchietto in nastro di acciaio.
PT79926B (en) Process for preparing 1,3-disubstituted 2-oxindoles useful as analgesic and anti-inflammatory agents
YU113988A (en) Process for preparing enanthiomeric (as,1'r)-3-/n-(metoxyacethyl)-n-(3-chlorine-2,6-dimethylphenyl)/-amino-tetrahydro-2-furanone

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MK4A Patent expired

Effective date: 20011215